Navigation Links
Pagoclone in Medical News

Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. About SANCTURA and SANCTURA XR SANCTURA(R) and SANCTURA XR(TM) belong to a class of anticholinergic compounds known as mus...

Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. About Endo Pharmaceuticals Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, ...

Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. About Endo Pharmaceuticals Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development...

Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. About Orion Corporation ( http://www.orion.fi ) Orion is a European pharmaceutical and diagnostics company which emphasises the de...

Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus To Announce First Quarter Fiscal 2008 Financial Results On Thursday, February 7, 2008

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Pharmaceuticals To Present at RBC Capital Markets Conference

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...

Indevus Pharmaceuticals to Present at Upcoming Investor Conferences

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...

With an aim to cure stuttering

...ng to the company. However, even larger trials were needed. According to New York Times, larger trials could take 2-3 years but if they succeed, pagoclone would become the first medicine for treating the problem. Research is concentrating on the idea that stammering is a neurological problem, which...
Pagoclone in Medical Technology

Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering

LEXINGTON, Mass., Sept. 26 /PRNewswire/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV ) today announced that it has signed a development, license and commercialization agreement with Teva Pharmaceutical Industries Ltd. for the exclusive, worldwide rights to pagoclone. Indevus previously anno...

Indevus Announces Presentation of Pagoclone Data at 47th Annual New Clinical Drug Evaluation Unit Meeting

Open-label Extension of Phase II Study Demonstrates Significant Additional Improvement for Patients on Pagoclone LEXINGTON, Mass., June 12, 2007 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. today announced that results from the Company's Phase II EXPRESS trial for pagoclone in persisten...

FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Safe Harbor Statement This press release contains forward-looking statements within the meaning of the Private Secur...

Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. PRO 2000 PRO 2000 (a naphthalene sulfonate polymer) is under development as a topical vaginal microbicide to prevent the s...

Indevus Pharmaceuticals Provides Update on PRO 2000 Program

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. PRO 2000 PRO 2000 (naphthalene sulfonate polymer) is a topical vaginal microbicide under development to prevent the sexual transmi...

Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Announces Submission of New Drug Application

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...

Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...

Indevus Reports Positive Data From Phase III NEBIDO Trial

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...
Pagoclone in Biological Technology

Indevus Pharmaceuticals Announces Release of 2008 Annual Report

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Contact: Michael W. Rogers EVP and Chief Financial Officer (781) 861-8444 Robin L. DeCarlo Sr. Directo...

Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results

...late stage development programs for octreotide and pagoclone are in full gear, and our successful $105 million ...ent with Teva for the development and marketing of pagoclone for the treatment of stuttering. In the first cal... Allergan -- Licensing of Worldwide Rights for pagoclone to Teva Corporate -- Issuance of U.S. Pa...

Indevus Pharmaceuticals to Present at Upcoming Investor Conferences

...000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. About the Jericho Road Episcopal Housing Initiative The Jericho Road Episcopal Housing Initiative creates quality homes for famili...

Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)

...IDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-l...

Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...

Indevus Announces Allergan as New Partner for SANCTURA Brand

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. About SANCTURA and SANCTURA XR SANCTURA(R) and SANCTURA(R) XR belong to a class of anticholinergic compounds known as muscarinic rec...

Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy

...(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering. Forward Looking Statements Except for the descriptions of historical facts contained herein, this press release contains forward-loo...
Other Tags
(Date:4/23/2014)... testosterone falls below normal levels are more likely to ... heart disease and type 2 diabetes. A new simple ... testing and possible treatment is described in an article ... publication from Mary Ann Liebert, Inc., publishers. The article ... Health website at http://www.liebertpub.com/jmh . ...
(Date:4/23/2014)... science, "simple and accessible detection methods that can ... resolution of a single cell inside that population ... engineer Chang Lu. , In the Royal Society ... has announced that he and his coworkers have ... location of a protein ( Chem. Sci. , ...
(Date:4/23/2014)... of probiotics, antioxidants and other nutritional compounds, more and ... is getting in on the action. But legitimate skepticism ... industry is responding with clinical research to shore up ... Chemical & Engineering News (C&EN), the weekly news ... Bomgardner, a senior editor at C&EN, writes that about ...
(Date:4/23/2014)... country as wealthy as the United States, it may come ... have access to adequate food due to lack of money ... Recent research at the University of Illinois using data from ... the seniors who are dealing with hunger are also facing ... percent of Americans over age 60 faced the threat of ...
(Date:4/23/2014)... a researcher from the Cancer Science Institute of Singapore ... identified the cancer specific stem cell which causes gastric ... new drugs for the treatment of this disease and ... by Dr Chan Shing Leng, Research Assistant Professor at ... cancer-specific variant of a cell surface protein, CD44v8-10, marks ...
Breaking Medicine News(10 mins):Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3
(Date:4/23/2014)... the source of a unique rhythmic sound, recorded for ... is the Antarctic minke whale ( Balaenoptera bonaerensis ). ... 1960s who thought it sounded like a duck, the ... the Southern Ocean, but its source has remained a ... team of researchers deployed acoustic tags on two Antarctic ...
(Date:4/23/2014)... Buenos Aires yesterday, Argentina joins the European Molecular ... The move strengthens the ties between the European ... Argentinian scientists access to EMBL,s world-class facilities and ... since its inception, fostering excellent life science research ... core of EMBL,s mission," says EMBL Director General ...
(Date:4/23/2014)... first cause of dementia and affects some 400,000 people ... been found. One of the reasons for this is ... cause alterations in nerve transmissions and the loss of ... from the Institute of Neuroscience at the Universitat Autnoma ... memory consolidation and were able to develop a gene ...
Breaking Biology News(10 mins):Scientists identify source of mysterious sound in the Southern Ocean 2Scientists identify source of mysterious sound in the Southern Ocean 3Loss of memory in Alzheimer's mice models reversed through gene therapy 2
Other Contents